Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program

J Am Acad Dermatol. 2018 Oct;79(4):777-778. doi: 10.1016/j.jaad.2018.06.024. Epub 2018 Jun 18.

Authors

Kelsey A Orrell¹, Morgan Murphrey¹, Ryan C Kelm¹, Harrison H Lee¹, David R Pease¹, Anne E Laumann¹, Dennis P West¹, Beatrice Nardone²

Affiliations

¹ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: b-nardone@northwestern.edu.

PMID: 29920313
DOI: 10.1016/j.jaad.2018.06.024

No abstract available

Publication types

Comparative Study

MeSH terms

Adverse Drug Reaction Reporting Systems*
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Australia
Canada
Databases, Factual
Disease Progression
Female
Humans
Inflammatory Bowel Diseases / chemically induced*
Inflammatory Bowel Diseases / physiopathology
Male
Risk Assessment

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
ixekizumab
secukinumab